Research progress on the role of interleukin-6 in tumor immune checkpoint inhibitor therapy

VernacularTitle:白细胞介素-6在肿瘤免疫检查点抑制剂治疗中的作用研究进展
Author: Zhu LINGLING ^{1
,

2} ; Zhang YANI ; Shi TINGTING ; Yu XIAOHUI ; Zhang JIUCONG
Author Information

1. 中国人民解放军联勤保障部队第九四〇医院消化内科(兰州市 730050)
2. 甘肃中医药大学第一临床医学院
Keywords: interleukin-6(IL-6); tumor; immune checkpoint inhibitors(ICIs); immune-related adverse events(irAEs)
From: Chinese Journal of Clinical Oncology 2024;51(11):585-589
CountryChina
Language:Chinese
Abstract: Immune checkpoint inhibitors(ICI),an immunotherapy,have an important role in the treatment of various cancers.However,ICIs induce several immune-related adverse events(irAEs).Interleukin(IL)-6 is an important inflammatory factor that promotes cancer progres-sion and modulates the clinical application of ICIs through various mechanisms.Herein,we postulate possible mechanisms that are involved in the ICI-regulatory effects mediated by the expression of the cytokine interleukin-6(IL-6),elucidate the effect of IL-6 on checkpoint-block-ade therapy and irAEs,and summarize the role of IL-6 signaling-targeted interventions in ICIs efficacy and irAEs management.